Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Expands By 64.7%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,800 shares, an increase of 64.7% from the December 15th total of 1,700 shares. Based on an average daily volume of 17,700 shares, the short-interest ratio is currently 0.2 days.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock traded down $0.05 during mid-day trading on Friday, reaching $0.10. 2,080 shares of the stock traded hands, compared to its average volume of 12,062. The business has a 50-day moving average of $0.07 and a 200 day moving average of $0.05. SAB Biotherapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.19.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.